Cargando…
A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
PURPOSE/BACKGROUND: Psychostimulant augmentation is considered a potential treatment strategy for individuals with major depressive disorder who do not adequately respond to antidepressant monotherapy. The primary objective of this 12-month open-label extension study was to evaluate the safety and t...
Autores principales: | Richards, Cynthia, Iosifescu, Dan V., Mago, Rajnish, Sarkis, Elias, Geibel, Brooke, Dauphin, Matthew, McIntyre, Roger S., Weisler, Richard, Brawman-Mintzer, Olga, Gu, Joan, Madhoo, Manisha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039401/ https://www.ncbi.nlm.nih.gov/pubmed/29912786 http://dx.doi.org/10.1097/JCP.0000000000000897 |
Ejemplares similares
-
A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy
por: Richards, Cynthia, et al.
Publicado: (2017) -
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
por: Adler, Lenard A, et al.
Publicado: (2009) -
A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
por: Gasior, Maria, et al.
Publicado: (2017) -
A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
por: Coghill, David R., et al.
Publicado: (2014) -
Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)